Impact of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine Use in Wound Management on Health Care Costs and Pertussis Cases

BACKGROUND: The Advisory Committee on Immunization Practices (ACIP) recommends the use of tetanus toxoid, reduced diphtheria toxoid, and acel-lular pertussis (Tdap) vaccine for routine wound management in adoles-cents and adults who require a tetanus toxoid-containing vaccine who were vaccinated ≥5 years earlier with tetanus toxoid, reduced diphtheria toxoid (Td) vaccine, and who have not previously received Tdap. OBJECTIVE: To estimate the overall budget and health impact of vaccinat-ing individuals presenting for wound management with Tdap instead of Td vaccine, the current standard of care in practices that do not use Tdap for purposes of wound management. METHODS: A decision-analytic economic model was developed to estimate the expected increase in direct medical costs and the expected number of cases of pertussis avoided associated with the use of Tdap instead of Td vaccine in the wound management setting. Patients eligible for Tdap wer